FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206282589> ?p ?o ?g. }

• W3206282589 abstract "Background and Objective: Myasthenia gravis (MG) is an autoimmune neuromuscular disease. Nearly 10–30% of patients with MG are refractory to conventional therapy. Rituximab (RTX), a monoclonal antibody targeting CD20, is increasingly used in autoimmune disorders. We performed a systematic review and meta-analysis to evaluate the effectiveness and safety of RTX for refractory MG. Methods: Studies published between January 1, 2000 and January 17, 2021 were searched in PubMed, EMBASE, Cochrane Library, and ClincalTrails.gov. Primary outcomes included proportion of patients achieving minimal manifestation status (MMS) or better and quantitative MG (QMG) score change from baseline. Secondary outcomes were glucocorticoids (GC) doses change from baseline and proportion of patients discontinuing oral immunosuppressants. Results: A total of 24 studies involving 417 patients were included in the meta-analysis. An overall 64% (95% confidence interval, 49–77%) of patients achieved MMS or better. The estimated reduction of QMG score was 1.55 (95% confidence interval, 0.88–2.22). The mean reduction of GC doses was 1.46 (95% confidence interval, 1.10–1.82). The proportion of patients discontinuing oral immunosuppressants was 81% (95% confidence interval, 66–93%). Subgroup analyses showed that the proportion of patients achieving MMS or better and discontinuing oral immunosuppressants was higher in MuSK-MG group than those in AChR-MG group. Improvement was more pronounced in patients with mild to moderate MG compared to those with severe MG. Moreover, the efficacy appeared to be independent of the dose of RTX. 19.6% of patients experienced adverse events, most of which were mild to moderate. Only one patient developed progressive multifocal leukoencephalopathy. Conclusions: RTX can alleviate the symptom of weakness, decrease QMG score and reduce the doses of steroids and non-steroid immunosuppressive agents in refractory MG. It is well-tolerated with few severe adverse events. Randomized controlled trials are urgently needed to study the efficacy of RTX in treating refractory MG and to identify the characteristics of patients who might respond well to RTX." @default.
• W3206282589 created "2021-10-25" @default.
• W3206282589 creator A5001420166 @default.
• W3206282589 creator A5003322678 @default.
• W3206282589 creator A5017612987 @default.
• W3206282589 creator A5020515556 @default.
• W3206282589 creator A5032653068 @default.
• W3206282589 creator A5062623310 @default.
• W3206282589 creator A5067951915 @default.
• W3206282589 date "2021-10-13" @default.
• W3206282589 modified "2023-10-16" @default.
• W3206282589 title "Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis" @default.
• W3206282589 cites W1607030948 @default.
• W3206282589 cites W1897013744 @default.
• W3206282589 cites W1964848281 @default.
• W3206282589 cites W1972087622 @default.
• W3206282589 cites W1973029867 @default.
• W3206282589 cites W2021398160 @default.
• W3206282589 cites W2024644107 @default.
• W3206282589 cites W2041047359 @default.
• W3206282589 cites W2046330020 @default.
• W3206282589 cites W2065357689 @default.
• W3206282589 cites W2072475795 @default.
• W3206282589 cites W2082722055 @default.
• W3206282589 cites W2086332067 @default.
• W3206282589 cites W2098419080 @default.
• W3206282589 cites W2109351747 @default.
• W3206282589 cites W2111680674 @default.
• W3206282589 cites W2133205391 @default.
• W3206282589 cites W2141231827 @default.
• W3206282589 cites W2156098321 @default.
• W3206282589 cites W2406546229 @default.
• W3206282589 cites W2461303519 @default.
• W3206282589 cites W2524675862 @default.
• W3206282589 cites W2555422834 @default.
• W3206282589 cites W2560852951 @default.
• W3206282589 cites W2584675601 @default.
• W3206282589 cites W2586254189 @default.
• W3206282589 cites W2591955898 @default.
• W3206282589 cites W2619783238 @default.
• W3206282589 cites W2742758273 @default.
• W3206282589 cites W2750731598 @default.
• W3206282589 cites W2760907988 @default.
• W3206282589 cites W2800388833 @default.
• W3206282589 cites W2801527958 @default.
• W3206282589 cites W2805892265 @default.
• W3206282589 cites W2909823939 @default.
• W3206282589 cites W2919577190 @default.
• W3206282589 cites W2923215055 @default.
• W3206282589 cites W2944474952 @default.
• W3206282589 cites W2953460189 @default.
• W3206282589 cites W2974168831 @default.
• W3206282589 cites W2991792334 @default.
• W3206282589 cites W2995776730 @default.
• W3206282589 cites W2998249298 @default.
• W3206282589 cites W3000276814 @default.
• W3206282589 cites W3014717815 @default.
• W3206282589 cites W3022437762 @default.
• W3206282589 cites W3023124841 @default.
• W3206282589 cites W3028682007 @default.
• W3206282589 cites W3031008534 @default.
• W3206282589 cites W3120182349 @default.
• W3206282589 cites W4211188347 @default.
• W3206282589 doi "https://doi.org/10.3389/fneur.2021.736190" @default.
• W3206282589 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8548630" @default.
• W3206282589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34721267" @default.
• W3206282589 hasPublicationYear "2021" @default.
• W3206282589 type Work @default.
• W3206282589 sameAs 3206282589 @default.
• W3206282589 citedByCount "13" @default.
• W3206282589 countsByYear W32062825892022 @default.
• W3206282589 countsByYear W32062825892023 @default.
• W3206282589 crossrefType "journal-article" @default.
• W3206282589 hasAuthorship W3206282589A5001420166 @default.
• W3206282589 hasAuthorship W3206282589A5003322678 @default.
• W3206282589 hasAuthorship W3206282589A5017612987 @default.
• W3206282589 hasAuthorship W3206282589A5020515556 @default.
• W3206282589 hasAuthorship W3206282589A5032653068 @default.
• W3206282589 hasAuthorship W3206282589A5062623310 @default.
• W3206282589 hasAuthorship W3206282589A5067951915 @default.
• W3206282589 hasBestOaLocation W32062825891 @default.
• W3206282589 hasConcept C121332964 @default.
• W3206282589 hasConcept C126322002 @default.
• W3206282589 hasConcept C142424586 @default.
• W3206282589 hasConcept C187960798 @default.
• W3206282589 hasConcept C197934379 @default.
• W3206282589 hasConcept C2776478404 @default.
• W3206282589 hasConcept C2778105408 @default.
• W3206282589 hasConcept C2779338263 @default.
• W3206282589 hasConcept C2780653079 @default.
• W3206282589 hasConcept C44249647 @default.
• W3206282589 hasConcept C71924100 @default.
• W3206282589 hasConcept C87355193 @default.
• W3206282589 hasConcept C90924648 @default.
• W3206282589 hasConcept C95190672 @default.
• W3206282589 hasConceptScore W3206282589C121332964 @default.
• W3206282589 hasConceptScore W3206282589C126322002 @default.
• W3206282589 hasConceptScore W3206282589C142424586 @default.
• W3206282589 hasConceptScore W3206282589C187960798 @default.
• W3206282589 hasConceptScore W3206282589C197934379 @default.

• next